202 related articles for article (PubMed ID: 31749438)
1. Clinical Value of PET/CT in Staging Melanoma and Potential New Radiotracers.
Annunziata S; Laudicella R; Caobelli F; Pizzuto DA; Aimn Working Group Y
Curr Radiopharm; 2020; 13(1):6-13. PubMed ID: 31749438
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Prognostic Value of
Albano D; Familiari D; Fornito MC; Scalisi S; Laudicella R; Galia M; Grassedonio E; Ruggeri A; Ganduscio G; Messina M; Spada M; Midiri M; Alongi P
Curr Radiopharm; 2020; 13(1):42-47. PubMed ID: 31595860
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients.
Reinhardt MJ; Joe AY; Jaeger U; Huber A; Matthies A; Bucerius J; Roedel R; Strunk H; Bieber T; Biersack HJ; Tüting T
J Clin Oncol; 2006 Mar; 24(7):1178-87. PubMed ID: 16505438
[TBL] [Abstract][Full Text] [Related]
4. The utility of PET-CT in the staging and management of advanced and recurrent malignant melanoma.
Twycross SH; Burger H; Holness J
S Afr J Surg; 2019 Sep; 57(3):44-49. PubMed ID: 31392864
[TBL] [Abstract][Full Text] [Related]
5. [Role of FDG PET-CT in cutaneous melanoma].
Nicol I; Chuto G; Gaudy-Marqueste C; Brenot-Rossi I; Grob JJ; Richard MA
Bull Cancer; 2008 Nov; 95(11):1089-101. PubMed ID: 19036682
[TBL] [Abstract][Full Text] [Related]
6. Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma.
Kumar R; Alavi A
Curr Opin Oncol; 2005 Mar; 17(2):154-9. PubMed ID: 15725921
[TBL] [Abstract][Full Text] [Related]
7. The role of FDG-PET-CT is limited in initial staging of nodal metastasis for thin cutaneous melanoma.
Cheng D; McNicoll CF; Kirgan D; Jones MS; Rivera MR; Doyle GM; De Guzman MD; Baynosa J; St Hill CR
Am J Surg; 2021 Apr; 221(4):737-740. PubMed ID: 32354604
[TBL] [Abstract][Full Text] [Related]
8.
Jaeger ZJ; Williams GA; Chen L; Mhlanga JC; Cornelius LA; Fields RC
J Surg Oncol; 2022 Mar; 125(3):525-534. PubMed ID: 34741547
[TBL] [Abstract][Full Text] [Related]
9. Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma?
Schaarschmidt BM; Grueneisen J; Stebner V; Klode J; Stoffels I; Umutlu L; Schadendorf D; Heusch P; Antoch G; Pöppel TD
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2093-2102. PubMed ID: 29876618
[TBL] [Abstract][Full Text] [Related]
10. F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review.
Schröer-Günther MA; Wolff RF; Westwood ME; Scheibler FJ; Schürmann C; Baumert BG; Sauerland S; Kleijnen J
Syst Rev; 2012 Dec; 1():62. PubMed ID: 23237499
[TBL] [Abstract][Full Text] [Related]
11. Role of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for the Detection of Recurrent Disease after Treatment of Malignant Melanoma.
Lee JW; Nam SB; Kim SJ
Oncology; 2019; 97(5):286-293. PubMed ID: 31437839
[TBL] [Abstract][Full Text] [Related]
12.
Lawal I; Lengana T; Ololade K; Boshomane T; Reyneke F; Modiselle M; Vorster M; Sathekge M
Nuklearmedizin; 2017 Jun; 56(3):83-89. PubMed ID: 28154879
[TBL] [Abstract][Full Text] [Related]
13. Fluorodeoxyglucose-PET in the management of malignant melanoma.
Kumar R; Mavi A; Bural G; Alavi A
Radiol Clin North Am; 2005 Jan; 43(1):23-33. PubMed ID: 15693645
[TBL] [Abstract][Full Text] [Related]
14. Whole-body
Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
[TBL] [Abstract][Full Text] [Related]
15. Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis.
Rodriguez Rivera AM; Alabbas H; Ramjaun A; Meguerditchian AN
Surg Oncol; 2014 Mar; 23(1):11-6. PubMed ID: 24556310
[TBL] [Abstract][Full Text] [Related]
16. [The role of preoperative (18)F-FDG PET-CT in lymphatic metastasis diagnosis of cutaneous malignant melanoma on extremities and trunk].
Zhang XX; Fang Y; Xu LB; Xu SF; Zhao ZG; Sun C; Ma PQ; Liu T; Yu SJ; Zhang WJ
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):372-378. PubMed ID: 29860765
[No Abstract] [Full Text] [Related]
17. A review of the literature for whole-body FDG PET in the management of patients with melanoma.
Schwimmer J; Essner R; Patel A; Jahan SA; Shepherd JE; Park K; Phelps ME; Czernin J; Gambhir SS
Q J Nucl Med; 2000 Jun; 44(2):153-67. PubMed ID: 10967625
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic accuracy of (18)F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma.
Gellén E; Sántha O; Janka E; Juhász I; Péter Z; Erdei I; Lukács R; Fedinecz N; Galuska L; Remenyik É; Emri G
J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1938-44. PubMed ID: 25753249
[TBL] [Abstract][Full Text] [Related]
19. Verification of musculoskeletal FDG-PET-CT findings performed for melanoma staging.
Mansour AA; Kelley MC; Hatmaker AR; Holt GE; Schwartz HS
Ann Surg Oncol; 2010 Apr; 17(4):1144-51. PubMed ID: 19967460
[TBL] [Abstract][Full Text] [Related]
20. The Role of PET/CT in the Era of Immune Checkpoint Inhibitors: State of Art.
Castello A; Lopci E
Curr Radiopharm; 2020; 13(1):24-31. PubMed ID: 31749440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
